You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞信升石药(1093.HK)评级至“跑赢大市”上调目标价至15.84港元
格隆汇 08-20 10:29

瑞信发表报告表示,上调对石药集团(1093.HK)投资评级,由“中性”升至“跑赢大市”,目标价由14.45港元升至15.84港元,此按现金流折现率作估值,表明旗下创新药物今年第二季销售强劲,该行决定上调对其2019年至2021年纯利预测各0.7%、1.9%及3.5%。

该行指出,石药第二季收入符合预期,由于研发开支较高,令其季内纯利低于该行预期,而管理层给予研发开支升幅稳定的指引。石药旗下创新药物销售同比增长56.4%,其中恩必普(NBP)增长39.5%,相信今年下半年增长势头可以持续。石药现价相当预测明年市盈率13.5倍,估值相较同业而言非常吸引。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account